CureVac’s Stock Journey Concludes Following BioNTech Acquisition

The independent public trading story for CureVac has reached its conclusion. BioNTech’s successful takeover has led to a suspension of the company’s shares. For shareholders, this marks the closing of one chapter, while the new owner immediately faces fresh legal complexities that may impact the strategic rationale behind the acquisition.

BioNTech valued the Tübingen-based firm at approximately $1.25 billion in an all-stock transaction. Shareholders received an effective price of about $5.46 per share, representing a 55% premium over CureVac’s three-month average stock price prior to the deal’s announcement. The offer garnered substantial support, with nearly 87% of shares tendered by mid-December. The remaining shares were acquired via a Read more...